-
公开(公告)号:US20230095701A1
公开(公告)日:2023-03-30
申请号:US17802806
申请日:2020-09-25
申请人: Zuoguang Zhang
发明人: Zuoguang Zhang , Hui Tian
IPC分类号: A61K31/7048 , A61K36/65 , A61P29/00
摘要: Use of albiflorin or a pharmaceutically acceptable salt thereof or an extract or a pharmaceutical composition containing albiflorin in the preparation of a medicament for preventing or treating coronavirus pneumonia, especially novel coronavirus pneumonia, or use thereof in the preparation of a medicament for treating prolonged symptoms of novel coronavirus pneumonia, performing rehabilitation conditioning after recovery of novel coronavirus pneumonia, or alleviating a possible sequela of novel coronavirus pneumonia, the sequela being depression, anxiety, sleep disorder, pain, palpitation, asthma, intestinal function disorder, or chronic fatigue syndrome. Albiflorin has the effects of anti-coronavirus, anti-inflammatory, inflammatory storm inhibition, human microecological balance regulation, etc., can comprehensively prevent and treat coronavirus-induced pneumonia, and can be prepared into medicaments, health care products or nutrition regulators for preventing or treating coronavirus pneumonia, especially novel coronavirus pneumonia.
-
公开(公告)号:US11534474B1
公开(公告)日:2022-12-27
申请号:US17389203
申请日:2021-07-29
申请人: Aytu Biopharma, Inc.
发明人: Bassam Damaj
IPC分类号: A61K36/8945 , A61K36/64 , A61K36/21 , A61K36/40 , A61K36/65 , A61P13/10 , A61K36/68 , A61K36/076 , A61K36/54 , A61K36/67 , A61K9/00 , A61K36/884
摘要: Oral compositions for supporting bladder function, reduce frequency of urination, and/or improve or maintain bladder control, suitable for oral administration, are described. Methods of use and uses are described, which include the step of administering an effective amount of the oral compositions to supporting bladder function, reduce frequency of urination, and/or improve or maintain bladder control.
-
公开(公告)号:US11484514B2
公开(公告)日:2022-11-01
申请号:US16957432
申请日:2018-12-20
发明人: Young Woo Lim , Ji Myeong Ok , Woon Ho Lee , Young Bin Kim
IPC分类号: A61P3/04 , A61K36/346 , A61K36/488 , A61K36/882 , A61K36/49 , A61K36/8994 , A61K36/31 , A61K36/736 , A61K36/8945 , A61K36/185 , A61K47/02 , A61K47/46 , A61K36/534 , A61K36/744 , A61K36/538 , A61K36/708 , A61K33/04 , A61K36/64 , A61K36/65 , A61K31/137 , A61K9/19 , A61K36/258 , A61K36/481 , A61K36/284 , A61K36/54 , A61K36/9068 , A61K36/076 , A61K36/752 , A61K36/725 , A61K36/734 , A61K36/575 , A61K36/884 , A61J3/06 , A61K9/28 , A61K36/17 , A61K36/62
摘要: An embodiment of the present invention provides a manufacturing method of an herbal medicinal tablet formulation for treating obesity which is prescribed based on Sasang constitutional medicine, comprises manufacturing a concentrated ephedra powder agent so that an ephedrine content is 3.0-4.0%; determining a weight of the concentrated ephedra powder agent according to each constitution of Sasang constitutional medicine, and manufacturing a side effect-preventing powder agent for each constitution to prevent and suppress side effects according to constitution of Sasang constitutional medicine with respect to the weight of the concentrated ephedra powder agent; mixing the concentrated ephedra powder agent and the side effect-preventing powder agent with a variance of a weight ratio therebetween in consideration of weight, obesity, constitution of Sasang constitutional medicine, and side effects; and tableting the mixture of the prepared ephedra powder agent and side effect-preventing powder agent.
-
公开(公告)号:US20220257688A1
公开(公告)日:2022-08-18
申请号:US17628235
申请日:2020-08-12
申请人: USCAREPHARM CO.,LTD
发明人: Suk Jin SONG , Byulnim OH , Mi-Ran CHA , Sunhee KANG , Juah SON , Yunsung LEE
IPC分类号: A61K36/65 , A61K36/537 , A61P3/06
摘要: The present invention relates to a composition comprising a Salvia miltiorrhiza or Paeonia lactiflora extract as an active ingredient for prevention or treatment of lipid metabolism disorder and, more particularly, provides a pharmaceutical composition and a health functional food composition, each comprising a Salvia miltiorrhiza extract, a Paeonia lactiflora extract, or an extract from a mixture of Salvia miltiorrhiza and Paeonia lactiflora as an active ingredient for prevention or treatment of lipid metabolism disorder. The composition prevents the differentiation of preadipocyte cells to adipocyte cells, reduces blood triglyceride and cholesterol levels, and effectively suppresses fatty liver and visceral fat formation and as such, can be advantageously used as a pharmaceutical and food composition for prevention, alleviation, or treatment of lipid metabolism disorder.
-
公开(公告)号:US20220151978A1
公开(公告)日:2022-05-19
申请号:US17431428
申请日:2020-02-17
发明人: AHARON M. EYAL , NOA RAZ , DANA BERNEMAN ZEITOUNI , ISO HELLER
IPC分类号: A61K31/352 , A61K31/05 , A61K31/085 , A61K31/045 , A61K31/01 , A61K31/015 , A61K36/29 , A61K36/88 , A61K36/71 , A61K36/8945 , A61K36/65 , A61K36/185 , A61K36/53 , A61K36/232 , A61K36/48 , A61K36/486 , A61K36/28 , A61P15/00 , A61P29/02
摘要: Provided is a kit comprising a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive; and a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof, and uses thereof in the treatment of pelvic pain arising from the female reproductive system. Further provided are methods of treatment of pelvic pain arising from a female reproductive system during a menstrual cycle, the method comprising administering during a first fraction of said menstrual cycle a first pharmaceutical composition comprising a first cannabinoid and optionally a first terpene and/or a first additive, and administering during a second fraction of said menstrual cycle a second pharmaceutical composition comprising at least one selected from the group consisting of a second cannabinoid, a second terpene, a second additive and combinations thereof.
-
公开(公告)号:US11324793B2
公开(公告)日:2022-05-10
申请号:US16848233
申请日:2020-04-14
申请人: YALE UNIVERSITY
发明人: Shwu-Huey Liu , Zaoli Jiang , Yung-Chi Cheng
IPC分类号: A61K36/00 , A61K36/725 , A61K36/484 , A61K36/539 , A61K36/65 , A61K31/4412 , A61K31/7068
摘要: This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy.
-
公开(公告)号:US20220062364A1
公开(公告)日:2022-03-03
申请号:US17010883
申请日:2020-09-03
申请人: Chen-Yu LEE
发明人: Hsuan-Ching TSENG , Da-Tong JU , Sung-Sen YANG , Wei-Te CHENG , Chen-Yu LEE , Yan-Chih LIAO
IPC分类号: A61K36/515 , A61K36/539 , A61K36/744 , A61K36/232 , A61K36/64 , A61K36/71 , A61K36/233 , A61K36/68 , A61K36/284 , A61K36/884 , A61K36/484 , A61K36/899 , A61K36/65 , A61K36/488 , A61K36/708 , A61K36/734 , A61K35/57 , A61P13/10 , A61P13/02 , A61P25/00 , A61P1/14
摘要: The present invention relates to a method for treating a side effect caused by bacillus Calmette-Guérin (BCG) perfusion therapy for bladder cancer. The method includes: administering a Chinese medicine composition to a subject in need thereof; wherein the Chinese medicine composition is an extract of a first mixture comprising gentiana scabra, scutellariae Radix, gardeniae fructus, angelicae sinensis Radix, rehmanniae radix, akebiae caulis, Bupleurum chinense, plantaginis Semen, Atractylodes lancea, rhizoma alismatis, and glycyrrhiza uralensis.
-
公开(公告)号:US20220023364A1
公开(公告)日:2022-01-27
申请号:US17279799
申请日:2019-09-24
申请人: KOLMAR BNH CO., LTD
发明人: Hyun Kyu KIM , Hak Sung LEE , Seul Ki KIM , Da Ae KWON , Young Sang KIM
IPC分类号: A61K36/232 , A61K36/234 , A61K36/65 , A23L33/105
摘要: Provided is a composition for alleviating fatigue or enhancing exercise capability including extracts or fractions of Angelica gigas, Cnidium officinale, and Paeonia lactiflora as active ingredients. The composition including the extracts or fractions of Angelica gigas, Cnidium officinale, and Paeonia lactiflora as active ingredients may effectively alleviate fatigue accumulated in the body and enhance exercise capability by multilaterally controlling various factors involved in physical fatigue and/or enhancement of exercise capability. Specifically, the composition may effectively control the factors related to fatigue by increasing the expression level of HO-1 by activating the Nrf-2 pathway. Also, since extracts of natural plants or fractions thereof are used as active ingredients, the composition is completely harmless to the human body and may be used safely.
-
公开(公告)号:US20210353701A1
公开(公告)日:2021-11-18
申请号:US17290664
申请日:2019-11-01
IPC分类号: A61K36/53 , A61P29/00 , A61K36/899 , A61K36/65 , A61K36/82 , A61K36/738 , A61K36/38 , A61K36/185 , G01N33/50
摘要: The present invention addresses the problem of providing an ultraviolet light-induced inflammation suppressing agent. The present invention is based on the finding that an alternative autophagy (Atg5/Atg7-independent autophagy) participates in the suppression of ultraviolet light-induced inflammation. Thus, the above problem is solved by providing an alternative autophagy inducing agent.
-
10.
公开(公告)号:US20210228667A1
公开(公告)日:2021-07-29
申请号:US17227370
申请日:2021-04-11
申请人: So Ngor Sally LEUNG
IPC分类号: A61K36/288 , A61K9/00 , A61K36/8962 , A61K36/15 , A61K36/82 , A61K36/52 , A61K36/81 , A61K36/65 , A61K36/236 , A61K36/87 , A61K36/752 , A61K36/889 , A61K36/235 , A61K36/31 , A61K45/06 , A61K47/06 , A61P13/12
摘要: The present invention relates to a health-care product composition for enriching asthenic disease, a preparation method therefor and use thereof. According to parts by mass, the raw materials required for preparing the composition comprise: 5 to 40 parts of dandelions, 10 to 120 parts of bulbous vegetables, 10 to 100 parts of condiment leafy vegetables, and 8 to 16 parts of fruits. The method for preparing the health-care product composition for enriching asthenic disease comprises the following steps: the raw materials such as dandelion, bulbous vegetables, and condiment leafy vegetables are pulverized and mixed to obtain a solid mixture; the solid mixture is leached with purified water and filtered to obtain a leaching juice; the leaching juice is concentrated to obtain a concentrated liquid; ethanol is added to the concentrated liquid to precipitate and remove impurities so as to obtain a refining solution; the refining solution is subjected to embedding treatment so as to obtain an extracting solution; the extracting solution is lyophilized to obtain a lyophilized powder of the health-care product composition for enriching asthenic disease. The health-care product composition for enriching asthenic disease prepared by the method contain no hormones, has no obvious toxic and side effects, and has the efficacy of enriching asthenic disease, tonifying kidney and strengthening yang.
-
-
-
-
-
-
-
-
-